RODMAN-&-RENSHAW arrive en tête à Wall Street en termes de contrats portant sur les biotechnologies en 2004. Une conférence prévue à Londres met en valeur des opportunités sectorielles prometteuses
Presse économique
Techvest Global Healthcare Conference 2004
NEW YORK--(BUSINESS WIRE)--May 6, 2004--Rodman & Renshaw, la banque d'affaires détenue par des fonds privés, a le plaisir d'annoncer qu'elle a conclu le plus grand nombre de contrats portant sur les biotechnologies à Wall Street en 2004, selon les statistiques de PlacementTracker.
(BW) Rodman & Renshaw Leads Wall Street for
Biotechnology Deals in 2004; Forthcoming London Conference Highlights
Exciting Sector Opportunities
Business Editors
Techvest Global Healthcare Conference 2004
NEW YORK--(BUSINESS WIRE)--May 6, 2004--Rodman & Renshaw, the
privately-held, full service investment bank, is very proud to
announce that it has been rated number 1 on Wall Street for the number
of biotechnology deals completed in 2004, according to statistics from
PlacementTracker.
Rodman & Renshaw has thus far raised over $300 million in 16
Private Placement transactions in 2004, and is ranked third in terms
of amount raised. Clients that Rodman & Renshaw has acted for include
Axonyx, Inc. ($50 million), Ariad Pharmaceuticals, Inc. ($43 million),
Vion Pharmaceuticals, Inc. ($35 million), SuperGen, Inc. ($34
million), and Prana Biotechnology Limited ($20 million). Most of the
biotechnology companies for which Rodman & Renshaw has helped raise
funds will be presenting at the Rodman & Renshaw Techvest Global
Healthcare Conference, taking place at the Claridge's Hotel, London,
UK, from 12th May to 14th May.
In 2003, Rodman & Renshaw completed over 30 financing
transactions, totalling over $500 million, and was ranked the number
one investment bank on Wall Street both in terms of deals closed and
amount of money raised, not only in the biotech sector, but including
financings across all sectors.
Rodman & Renshaw is also pleased to announce that Dr. Elmer Piros,
Senior Biotechnology Analyst, has been rated number 2 analyst in terms
of portfolio performance in the biotechnology arena over the past
year. This rating was generated by StarMine, tools that evaluate
analysts by simulating portfolios based on the analyst's
recommendations.
John J. Borer, III, Senior Managing Director at Rodman & Renshaw
said, "Today's announcements clearly highlight Rodman & Renshaw's
expertise and dedicated focus in the biotechnology field. Our
investment banking team has consistently demonstrated its proven
ability to assist emerging biotechnology companies to raise the funds
that they need to support and maintain their desired growth
objectives. Concurrently, our institutional research department has
excelled in difficult market conditions to provide investors with
timely, nuanced advice fundamental to optimal stock selection. We are
extremely proud of these achievements and our continued commitment to
the biotechnology field will be in full display at our upcoming Global
Healthcare Conference in London."
The Rodman & Renshaw Techvest Global Healthcare conference will
feature presentations from 160 emerging growth biotechnology
companies, both from the US and Europe, and is designed to give
investors access to some of the most exciting opportunities in the
biotech and healthcare space globally. Investors are invited to
register, free of charge, via the Rodman & Renshaw website at
www.rodmanandrenshaw.com.
Rodman & Renshaw, LLC is a privately held, full-service investment
bank committed to fostering the long-term success of emerging growth
companies through capital raising, strategic advice, insightful
research, and the development of institutional support.
CONTACT: Conference enquiries:
Rodman & Renshaw, LLC
Lily Khaykina, 212-356-0529
LK@rodmanandrenshaw.com
or
Press enquiries:
Citigate Dewe Rogerson
Emma Timewell, 44-0-20-7282-1043
emma.timewell@citigatedr.co.uk
ESHEET : 4633911
© CompanynewsGroup